State of Alaska Department of Revenue Has $5.87 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

State of Alaska Department of Revenue lifted its holdings in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 33.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 272,875 shares of the company’s stock after purchasing an additional 68,105 shares during the period. State of Alaska Department of Revenue’s holdings in Kenvue were worth $5,874,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Gradient Investments LLC lifted its holdings in Kenvue by 17.3% during the 4th quarter. Gradient Investments LLC now owns 743,399 shares of the company’s stock worth $16,005,000 after buying an additional 109,478 shares during the period. Caprock Group LLC raised its position in shares of Kenvue by 210.6% during the fourth quarter. Caprock Group LLC now owns 42,484 shares of the company’s stock worth $915,000 after acquiring an additional 28,805 shares during the last quarter. Global Retirement Partners LLC lifted its stake in shares of Kenvue by 95.6% in the fourth quarter. Global Retirement Partners LLC now owns 2,726 shares of the company’s stock worth $58,000 after acquiring an additional 1,332 shares during the period. Blue Trust Inc. bought a new stake in Kenvue in the fourth quarter valued at approximately $53,000. Finally, Franklin Street Advisors Inc. NC increased its position in Kenvue by 8.5% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 210,597 shares of the company’s stock valued at $4,534,000 after purchasing an additional 16,580 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group began coverage on shares of Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target on the stock. UBS Group boosted their target price on shares of Kenvue from $20.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, December 19th. Royal Bank of Canada lowered their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. Finally, JPMorgan Chase & Co. cut their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.42.

Get Our Latest Report on Kenvue

Kenvue Trading Up 0.0 %

Shares of NYSE:KVUE opened at $21.46 on Monday. Kenvue Inc. has a 52-week low of $17.82 and a 52-week high of $27.80. The business’s 50 day simple moving average is $20.02 and its two-hundred day simple moving average is $20.23. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUEGet Free Report) last issued its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.78 billion. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. As a group, equities analysts forecast that Kenvue Inc. will post 1.17 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were issued a $0.20 dividend. The ex-dividend date was Tuesday, February 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.73%.

Kenvue Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

See Also

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.